Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Work In Process (2025)

Crinetics Pharmaceuticals (CRNX) has 1 years of Work In Process data on record, last reported at $2.0 million in Q4 2025.

  • For Q4 2025, Work In Process changed N/A year-over-year to $2.0 million; the TTM value through Dec 2025 reached $2.0 million, changed N/A, while the annual FY2025 figure was $2.0 million, N/A changed from the prior year.
  • Work In Process reached $2.0 million in Q4 2025 per CRNX's latest filing.
  • Across five years, Work In Process topped out at $2.0 million in Q4 2025 and bottomed at $2.0 million in Q4 2025.